Themis Medicare Limited (THEMISMED) fundamentals
Themis Medicare Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as THEMISMED (ISIN INE083B01024). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Themis Medicare Limited does
Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. The Company specializes in manufacturing a range of products for application areas like pain management, critical care and anti-infectives. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more.
Valuation and market data
| Last close | ₹132.00 |
|---|---|
| Market capitalisation | ₹1,215 crore |
| Enterprise value | ₹1,238 crore |
| P/E (TTM) | 0.00 |
| Price to book | 3.02 |
| Price to sales (TTM) | 3.57 |
| Book value per share | ₹43.73 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Apr 02 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹352 crore | ₹-13 crore | ₹-14 crore | 0.00 |
| Mar 2025 | ₹410 crore | ₹34 crore | ₹24 crore | 2.60 |
| Mar 2024 | ₹387 crore | ₹35 crore | ₹25 crore | 2.69 |
| Mar 2023 | ₹366 crore | ₹59 crore | ₹43 crore | 4.70 |
| Mar 2022 | ₹401 crore | ₹84 crore | ₹62 crore | 66.91 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 67.1% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 32.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.